Zevra Therapeutics, Inc. (ZVRA) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | |
| Borrowing debt due after one year | 0.00 USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 221.57M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Excluding Current Maturities |
| Total assets | 302.71M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $0.00 | (m) | $221.57M | $302.71M | (m) |
| 2026-03-31 | (m) | (m) | (m) | $0.00 | (m) | $200.62M | $278.58M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $61.93M | (m) | $191.01M | $284.73M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $61.31M | (m) | $199.51M | $270.12M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $60.69M | (m) | $202.61M | $256.28M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $60.09M | (m) | $62.63M | $172.71M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $59.50M | (m) | $69.50M | $178.13M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $58.90M | (m) | $89.38M | $191.55M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $58.33M | (m) | $49.26M | $144.41M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $5.07M | (m) | $67.74M | $172.33M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $781.00K | (m) | (m) | $11.20M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $781.00K | (m) | (m) | $12.33M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |